Hepatocellular carcinoma in extremely elderly patients:An analysis of clinical characteristics,prognosis and patient survival

瞄准：80 年或更多与肝细胞癌(HCC ) 识别病人的临床、预示的特征。方法：有 HCC 的 1310 个病人的一个总数在这研究被包括。80 年或更多的 91 个病人在 HCC 的诊断的时候被定义为极其老的组。】 或 = 的 234 个病人 50 年但是不到 60 年被认为是非老的组。结果：两性比率(到女性的男性) 比在非老的组在极其老的组(0.90:1 ) 是显著地更低的(3.9:1， P 【 0.001 ) 。为 HBsAg 的积极的率在极其老的组和为显然在极其老的组增加的 HBsAg 和 HCVAb 否定的病人的比例是显著地更低的(P 【 0.001 ) 。在下列参数没有有效差量：肿瘤，分级的孩子呸，肿瘤阶段，门静脉血栓形成或腹水的存在，和为 HCVAb 的积极的率的直径和数字。极其老的病人经常没收到外科疗法(P 【 0.001 ) 并且他们是更可能的收到保守疗法(P 【 0.01 ) 。基于与在二个组之间的全面病人比较的 Kaplan-Meier 方法在幸存曲线没有有效差量。然而，幸存曲线在有阶段 I/II 的极其老的病人是显著地更坏的，上演 I/II，孩子呸分级与非老的组比较的肝硬化。死亡的原因没在病人之中不同，并且大多数盒子甚至在极其老的病人死于肝相关的疾病。结论：在有好肝功能和好表演地位的病人，为 HCC 的好攻击的治疗可能改进幸存率，甚至在极其老的病人。

Efficacy of 5-Fluorouracil and High-Concentration Cisplatin Suspended in Lipiodol by Short-Term Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

Background: Since advanced hepatocellular carcinoma (HCC) is potentially fatal, and patients’ quality of life (QOL) often deteriorates during their treatment, improving the prognosis and QOL of patients given chemotherapy is very important. In addition, cost-effective treatments are highly desirable when chemotherapy must be given repeatedly. The aim of this study was to evaluate the efficacy and usefulness of 5-fluorouracil (5-FU) and high-concentration cisplatin by short-term hepatic arterial infusion chemotherapy (3-day FPL) in advanced HCC patients. Methods: Thirty patients with unresectable advanced HCC were enrolled. The patients underwent hepatic arterial infusion chemotherapy via the implanted port system with 5-FU on days 1 - 3 and a fine-powder formulation of cisplatin in suspended pre-warmed lipiodol on day 2 every 4 to 10 weeks. Tumor response was assessed one month later with CT. Results: All patients had evidence of portal vein invasion (Vp2-4). Four patients achieved a complete response (CR), 8 patients achieved a partial response (PR), and 7 patients had stable disease (SD). The median progression-free survival (PFS) and overall survival (OS) were 198 days and 452 days, respectively. The OS was significantly longer in the successful disease control group (CR, PR, and SD) than in the progressive disease group (P < 0.005). Conclusions: Three-day FPL was effective and tolerable in advanced HCC patients due to its shorter time of administration than conventional FP therapy. Therefore, repetitive 3-day FPL appears useful and contributes to improving the prognosis and QOL of patients with advanced HCC. In addition, this protocol is a cost-effective treatment.

Overexpression of NK2 inhibits liver regeneration after partial hepatectomy in mice

AIM: To investigate the in vivo effects of NK2 on liver regeneration after partial hepatectomy (PH). METHODS: Survival after PH was observed with 21 NK2 transgenic mice and 23 wild-type (WT) mice over 10 d. Liver regeneration was analyzed using histology and immunohistochemistry. Expressions of genes were analyzed using Northern blot analysis, immunoprecipitation and immunoblotting, and reverse transcriptase polymerase chain reaction assay. KaplanMeier method and the log-rank test were used for ahalyzing the survival after PH. Differences in the resultsof immunohistochemistry and percentage of liver regeneration was determined by the Student's t-test. RESULTS: More than half of NK2 transgenic mice died within 48 h after PH. After PH, increased deposition of small lipid droplets in hepatocytes was evident and hepatic proliferation was inhibited in NK2 transgenic mice. The hepatic expression and kinase activity of HGF receptor, c-Met, were unchanged among WT mice and NK2 transgenic mice after PH. The expression of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in liver tissues were prolonged in NK2 transgenic mice that died after PH.CONCLUSION: Our findings indicate that overexpression of NK2 inhibits liver regeneration after PH.

Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C:A randomized controlled clinical trial

瞄准：为了与锌学习干扰素(IFN ) 和 ribavirin 的治疗学的效果，与长期的丙肝在病人上补充病毒(HCV ) 感染。方法：组织学地证实与遗传型 1b 和 HCV 的超过 100 KIU/mL 有长期的 HCV 感染的 102 个病人的一个总数随机被分到学习的每只手臂，各个收到了为 4 wk 的干扰素( IFN-alpha-2b )日报每隔一天由一样的剂量跟随了为的 pegylated 的1000万个单位加 ribavirin ( 600 或 800 mg/d 取决于体重)的 20 wk ，与或没有 polaprezinc ( 150 mg/d )口头上地为 24 wk 。主要端点是在浆液定义为否定 HCV-RNA 的持续 virological 反应(SVR ) 6 瞬间术后疗法。结果：比在另外的组(P【0.05 ) 除了在双治疗组的更多的女性在在二个组之间的临床的背景没有差别。SVR 在 33.3% 三倍的治疗组和 33.3% 双治疗组被观察。副作用是几乎，在两个的一样除了胃肠的症状组织，它是在三倍的治疗组(P=0.019 ) 的更少。结论：一起考虑了，加为有遗传型 1b 和高病毒的负担的 HCV 感染病人的 IFN 和 ribavirin 的锌的三倍的治疗不除了胃肠的副作用的更低的发生比双治疗好。